Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Drug-Loaded Elastin-Like Polypeptide-Collagen Hydrogels with High Modulus for Bone Tissue Engineering.

Pal P, Nguyen QC, Benton AH, Marquart ME, Janorkar AV.

Macromol Biosci. 2019 Aug 2:e1900142. doi: 10.1002/mabi.201900142. [Epub ahead of print]

PMID:
31373780
2.

Staphylococcus aureus Superantigen-Like Protein SSL1: A Toxic Protease.

Tang A, Caballero AR, Bierdeman MA, Marquart ME, Foster TJ, Monk IR, O'Callaghan RJ.

Pathogens. 2019 Jan 1;8(1). pii: E2. doi: 10.3390/pathogens8010002.

3.

Antibiotic susceptibility, cytotoxicity, and protease activity of viridans group streptococci causing endophthalmitis.

Marquart ME, Benton AH, Galloway RC, Stempak LM.

PLoS One. 2018 Dec 21;13(12):e0209849. doi: 10.1371/journal.pone.0209849. eCollection 2018.

4.

Mechanism of Pseudomonas aeruginosa Small Protease (PASP), a Corneal Virulence Factor.

Tang A, Caballero AR, Marquart ME, Bierdeman MA, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5993-6002. doi: 10.1167/iovs.18-25834.

5.

The Role of Pneumococcal Virulence Factors in Ocular Infectious Diseases.

Benton AH, Marquart ME.

Interdiscip Perspect Infect Dis. 2018 Nov 13;2018:2525173. doi: 10.1155/2018/2525173. eCollection 2018. Review.

6.

Exogenous Streptococcus pneumoniae Endophthalmitis in Diabetic Rabbits.

Benton AH, Fulton LK, Marquart ME.

Sci Rep. 2017 Apr 7;7:46196. doi: 10.1038/srep46196.

7.

Differential bacterial gene expression during experimental pneumococcal endophthalmitis.

Thornton JA, Tullos NA, Sanders ME, Ridout G, Wang YD, Taylor SD, McDaniel LS, Marquart ME.

Ophthalmic Res. 2015;53(3):149-61. doi: 10.1159/000371713. Epub 2015 Mar 12.

8.

Effective release of a broad spectrum antibiotic from elastin-like polypeptide-collagen composite.

Anderson TR, Marquart ME, Janorkar AV.

J Biomed Mater Res A. 2015 Feb;103(2):782-90. doi: 10.1002/jbm.a.35219. Epub 2014 Jun 3.

9.

Modulation of immune signaling, bacterial clearance, and corneal integrity by toll-like receptors during streptococcus pneumoniae keratitis.

Tullos NA, Thompson HW, Taylor SD, Sanders M, Norcross EW, Tolo I, Moore Q, Marquart ME.

Curr Eye Res. 2013 Oct;38(10):1036-48. doi: 10.3109/02713683.2013.804094. Epub 2013 Jul 10.

PMID:
23841825
10.

The cholesterol-dependent cytolysin pneumolysin from Streptococcus pneumoniae binds to lipid raft microdomains in human corneal epithelial cells.

Taylor SD, Sanders ME, Tullos NA, Stray SJ, Norcross EW, McDaniel LS, Marquart ME.

PLoS One. 2013;8(4):e61300. doi: 10.1371/journal.pone.0061300. Epub 2013 Apr 5.

11.

Pseudomonas aeruginosa small protease (PASP), a keratitis virulence factor.

Tang A, Caballero AR, Marquart ME, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2013 Apr 17;54(4):2821-8. doi: 10.1167/iovs.13-11788.

12.

Passive immunization with Pneumovax® 23 and pneumolysin in combination with vancomycin for pneumococcal endophthalmitis.

Sanders ME, Taylor S, Tullos N, Norcross EW, Moore QC 3rd, Thompson H, King LB, Marquart ME.

BMC Ophthalmol. 2013 Mar 11;13:8. doi: 10.1186/1471-2415-13-8.

13.

Infectious keratitis: secreted bacterial proteins that mediate corneal damage.

Marquart ME, O'Callaghan RJ.

J Ophthalmol. 2013;2013:369094. doi: 10.1155/2013/369094. Epub 2013 Jan 8.

14.

Pathogenesis of A Clinical Ocular Strain of Streptococcus pneumoniae and the Interaction of Pneumolysin with Corneal Cells.

Norcross EW, Sanders ME, Moore QC 3rd, Marquart ME.

J Bacteriol Parasitol. 2011;2(2):108.

15.

Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis.

Norcross EW, Sanders ME, Moore QC 3rd, Taylor SD, Tullos NA, Caston RR, Dixon SN, Nahm MH, Burton RL, Thompson H, McDaniel LS, Marquart ME.

Invest Ophthalmol Vis Sci. 2011 Nov 29;52(12):9232-43. doi: 10.1167/iovs.10-6968.

16.

"Boom" and "Bust" cycles in virus growth suggest multiple selective forces in influenza a evolution.

Thangavel RR, Reed A, Norcross EW, Dixon SN, Marquart ME, Stray SJ.

Virol J. 2011 Apr 18;8:180. doi: 10.1186/1743-422X-8-180.

17.

Animal models of bacterial keratitis.

Marquart ME.

J Biomed Biotechnol. 2011;2011:680642. doi: 10.1155/2011/680642. Epub 2011 Jan 4. Review.

18.

Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis.

Sanders ME, Tullos NA, Taylor SD, Norcross EW, King LB, Tolo I, Marquart ME.

Curr Eye Res. 2010 Dec;35(12):1142-7. doi: 10.3109/02713683.2010.512114.

19.

The Streptococcus pneumoniae capsule is required for full virulence in pneumococcal endophthalmitis.

Sanders ME, Norcross EW, Robertson ZM, Moore QC 3rd, Fratkin J, Marquart ME.

Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):865-72. doi: 10.1167/iovs.10-5513. Print 2011 Feb.

20.

Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis.

Sanders ME, Norcross EW, Moore QC 3rd, Fratkin J, Thompson H, Marquart ME.

J Ocul Pharmacol Ther. 2010 Dec;26(6):571-7. doi: 10.1089/jop.2010.0077. Epub 2010 Oct 29.

21.

Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.

Sanders ME, Moore QC 3rd, Norcross EW, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME.

Cornea. 2011 Jan;30(1):83-90. doi: 10.1097/ICO.0b013e3181e2f0f3.

PMID:
20847656
22.

Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection.

Norcross EW, Tullos NA, Taylor SD, Sanders ME, Marquart ME.

Curr Eye Res. 2010 Sep;35(9):787-98. doi: 10.3109/02713683.2010.492462.

23.

Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.

Norcross EW, Sanders ME, Moore Q 3rd, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME.

J Ocul Pharmacol Ther. 2010 Jun;26(3):237-43. doi: 10.1089/jop.2009.0154.

PMID:
20565309
24.

Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.

Sanders ME, Moore QC 3rd, Norcross EW, Shafiee A, Marquart ME.

J Ocul Pharmacol Ther. 2010 Apr;26(2):193-8. doi: 10.1089/jop.2009.0121.

PMID:
20334537
25.

Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.

Sanders ME, Norcross EW, Moore QC 3rd, Shafiee A, Marquart ME.

Cornea. 2009 Oct;28(9):1055-60. doi: 10.1097/ICO.0b013e31819e34cb.

PMID:
19724203
26.

A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model.

Sanders ME, Norcross EW, Moore QC, Onwubiko C, King LB, Fratkin J, Marquart ME.

Clin Ophthalmol. 2008 Dec;2(4):793-800.

27.

Development of a Streptococcus pneumoniae keratitis model in mice.

Moore QC 3rd, McCormick CC, Norcross EW, Onwubiko C, Sanders ME, Fratkin J, McDaniel LS, O'Callaghan RJ, Marquart ME.

Ophthalmic Res. 2009;42(3):141-6. doi: 10.1159/000229028. Epub 2009 Jul 23.

28.

Properties of PASP: a Pseudomonas protease capable of mediating corneal erosions.

Tang A, Marquart ME, Fratkin JD, McCormick CC, Caballero AR, Gatlin HP, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3794-801. doi: 10.1167/iovs.08-3107. Epub 2009 Feb 28.

29.

Protection from Streptococcus pneumoniae keratitis by passive immunization with pneumolysin antiserum.

Green SN, Sanders M, Moore QC 3rd, Norcross EW, Monds KS, Caballero AR, McDaniel LS, Robinson SA, Onwubiko C, O'Callaghan RJ, Marquart ME.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):290-4. doi: 10.1167/iovs.07-0492.

30.

Age-related differences in rabbits during experimental Staphylococcus aureus keratitis.

O'Callaghan RJ, McCormick CC, Caballero AR, Marquart ME, Gatlin HP, Fratkin JD.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5125-31.

PMID:
17962465
31.

Cholesterol as treatment for pneumococcal keratitis: cholesterol-specific inhibition of pneumolysin in the cornea.

Marquart ME, Monds KS, McCormick CC, Dixon SN, Sanders ME, Reed JM, McDaniel LS, Caballero AR, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2661-6.

32.

Corneal virulence of Pseudomonas aeruginosa elastase B and alkaline protease produced by Pseudomonas putida.

Thibodeaux BA, Caballero AR, Marquart ME, Tommassen J, O'Callaghan RJ.

Curr Eye Res. 2007 Apr;32(4):373-86.

PMID:
17453960
33.

Localization of PcsB of Streptococcus pneumoniae and its differential expression in response to stress.

Mills MF, Marquart ME, McDaniel LS.

J Bacteriol. 2007 Jun;189(12):4544-6. Epub 2007 Apr 20.

34.

The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis.

McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ.

Curr Eye Res. 2006 Mar;31(3):225-30.

PMID:
16531279
35.

Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.

Caballero AR, Marquart ME, O'Callaghan RJ, Thibodeaux BA, Johnston KH, Dajcs JJ.

Curr Eye Res. 2006 Jan;31(1):23-9.

PMID:
16421016
36.

Identification of a novel secreted protease from Pseudomonas aeruginosa that causes corneal erosions.

Marquart ME, Caballero AR, Chomnawang M, Thibodeaux BA, Twining SS, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3761-8.

PMID:
16186360
37.

Pseudomonas aeruginosa protease IV: a corneal virulence factor of low immunogenicity.

Thibodeaux BA, Caballero AR, Dajcs JJ, Marquart ME, Engel LS, O'Callaghan RJ.

Ocul Immunol Inflamm. 2005 Apr-Jun;13(2-3):169-82.

PMID:
16019676
38.

Pathogenesis of Staphylococcus in the rabbit anterior chamber.

Girgis DO, Reed JM, Monds KS, Dajcs JJ, Marquart ME, Thibodeaux BA, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1371-8.

PMID:
15790904
39.

Ocular virulence of capsule-deficient streptococcus pneumoniae in a rabbit keratitis model.

Reed JM, O'Callaghan RJ, Girgis DO, McCormick CC, Caballero AR, Marquart ME.

Invest Ophthalmol Vis Sci. 2005 Feb;46(2):604-8.

PMID:
15671288
40.

Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.

Thibodeaux BA, Dajcs JJ, Caballero AR, Marquart ME, Girgis DO, O'Callaghan RJ.

Curr Eye Res. 2004 May;28(5):337-42.

PMID:
15287370
41.

Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):1948-52.

42.

Calcium and magnesium enhance the production of Pseudomonas aeruginosa protease IV, a corneal virulence factor.

Marquart ME, Dajcs JJ, Caballero AR, Thibodeaux BA, O'Callaghan RJ.

Med Microbiol Immunol. 2005 Jan;194(1-2):39-45. Epub 2003 Nov 20.

PMID:
14628143
43.

Molecular analysis of Pseudomonas aeruginosa protease IV expressed in Pseudomonas putida.

Traidej M, Caballero AR, Marquart ME, Thibodeaux BA, O'Callaghan RJ.

Invest Ophthalmol Vis Sci. 2003 Jan;44(1):190-6.

PMID:
12506074
44.

Identification of the active site residues of Pseudomonas aeruginosa protease IV. Importance of enzyme activity in autoprocessing and activation.

Traidej M, Marquart ME, Caballero AR, Thibodeaux BA, O'Callaghan RJ.

J Biol Chem. 2003 Jan 24;278(4):2549-53. Epub 2002 Nov 4.

45.

The region of the HSV-1 latency-associated transcript required for epinephrine-induced reactivation in the rabbit does not include the 2.0-kb intron.

Jarman RG, Loutsch JM, Devi-Rao GB, Marquart ME, Banaszak MP, Zheng X, Hill JM, Wagner EK, Bloom DC.

Virology. 2002 Jan 5;292(1):59-69.

46.

Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis.

Dajcs JJ, Moreau JM, Thibodeaux BA, Traidej M, Austin MS, Marquart ME, Stroman DW, O'Callaghan RJ.

Cornea. 2001 Nov;20(8):878-80.

PMID:
11685070
47.

Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.

Loutsch JM, Sainz B Jr, Marquart ME, Zheng X, Kesavan P, Higaki S, Hill JM, Tal-Singer R.

Antimicrob Agents Chemother. 2001 Jul;45(7):2044-53.

48.

Stress-associated immunomodulation and herpes simplex virus infections.

Sainz B, Loutsch JM, Marquart ME, Hill JM.

Med Hypotheses. 2001 Mar;56(3):348-56.

PMID:
11359358
49.
50.

Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases.

Caballero AR, Moreau JM, Engel LS, Marquart ME, Hill JM, O'Callaghan RJ.

Anal Biochem. 2001 Mar;290(2):330-7.

PMID:
11237336

Supplemental Content

Loading ...
Support Center